E-Med taps new president and CEO

Article

Raytheon E-Systems Medical Electronics (E-Med) has named RonaldFord as president and CEO of the San Antonio, TX, teleradiologycompany. Ford replaces James Karlak, who left E-Med in a restructuringin July (SCAN 7/17/96).Ford previously was director of

Raytheon E-Systems Medical Electronics (E-Med) has named RonaldFord as president and CEO of the San Antonio, TX, teleradiologycompany. Ford replaces James Karlak, who left E-Med in a restructuringin July (SCAN 7/17/96).

Ford previously was director of product assurance at the Garland,TX, division of Raytheon E-Systems, where he led the developmentand production of large-scale signal-processing systems. The Garlandunit took over R&D responsibilities for E-Med's PACSPro/DXproduct line as part of the July restructuring, leaving E-Medto concentrate on teleradiology and miniPACS components.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.